Monograph of Cetirizine

Introduction

Cetirizine is a second‑generation antihistamine that selectively antagonizes peripheral H1 receptors. It is widely employed in the treatment of allergic disorders such as rhinitis, urticaria, and atopic dermatitis. The present monograph aims to provide a comprehensive overview of cetirizine, encompassing its historical development, pharmacological properties, and clinical applications. Graduate students and trainees in pharmacy and medicine will find this discussion useful for understanding the drug’s role within therapeutic regimens.

Learning Objectives

• Identify the structural features that distinguish cetirizine from first‑generation antihistamines.
• Explain the absorption, distribution, metabolism, and excretion (ADME) profile of cetirizine.
• Describe the pharmacodynamic actions of cetirizine at the H1 receptor site.
• Recognize common drug interactions and contraindications associated with cetirizine use.
• Apply knowledge of cetirizine pharmacology to clinical case scenarios involving allergic disease management.

Fundamental Principles

Chemical Structure and Classification

Cetirizine is a piperazine derivative characterized by a 1‑piperazinyl‑3‑pyridyl structure. Its molecular formula is C₁₇H₂₂ClN₃O₃, with a molecular weight of 404.92 g/mol. Compared with first‑generation antihistamines, cetirizine possesses a tertiary amine group that confers reduced lipid solubility and, consequently, limited central nervous system penetration. This structural attribute underpins its lower sedative profile.

Receptor Binding and Pharmacodynamics

Cetirizine competitively binds to peripheral H1 receptors, thereby blocking the action of histamine on vascular endothelial cells, smooth muscle, and sensory nerve endings. The affinity of cetirizine for the H1 receptor is approximately 1 × 10⁻⁹ M, which is comparable to other second‑generation agents. By preventing histamine release, cetirizine reduces vasodilation, capillary permeability, and pruritus.

Pharmacokinetic Parameters

• Absorption: Oral bioavailability is around 80 % when administered as the hydrochloride salt. Peak plasma concentration (C_max) is typically reached within 1–3 h post‑dose.
• Distribution: The volume of distribution (V_d) is approximately 20 L, indicating moderate tissue penetration. Plasma protein binding is ~20 %.
• Metabolism: Cetirizine undergoes minimal hepatic biotransformation. The primary metabolic route involves glucuronidation to form N‑glucuronide conjugates.
• Excretion: Renal clearance accounts for ~90 % of total clearance. The elimination half‑life (t_1/2) is 8–12 h in healthy adults, extending to 12–24 h in patients with impaired renal function.

Key Terminology

• H1 Receptor Antagonist – a compound that blocks histamine binding to H1 receptors.
• Peripheral Selectivity – the ability of a drug to act primarily outside the central nervous system.
• Glucuronidation – a phase II metabolic process that attaches glucuronic acid to a substrate, increasing solubility.
• Renal Clearance (Cl_renal) – the volume of plasma from which the drug is completely removed by the kidneys per unit time.

Detailed Explanation

Absorption and Bioavailability

Upon oral administration, cetirizine dissolves rapidly in gastrointestinal fluids. The drug’s pKa is 7.6, ensuring that a significant proportion remains in the ionized form at physiological pH. Ionized molecules exhibit limited membrane permeability; however, cetirizine’s moderate lipophilicity facilitates passive diffusion across enterocyte membranes. The drug’s absorption is largely independent of food intake, although a high-fat meal can modestly delay C_max by 1 h.

Distribution Dynamics

The distribution of cetirizine is governed by its plasma protein binding and lipophilicity. With 20 % protein binding, 80 % of the drug remains free for tissue exchange. The V_d of 20 L suggests that the drug distributes primarily within the plasma and extracellular fluid compartments. Limited penetration across the blood‑brain barrier (BBB) is attributable to the drug’s ionized state and the presence of efflux transporters such as P-glycoprotein, which actively extrude the compound from the central nervous system.

Metabolism and Excretion Pathways

Cetirizine undergoes negligible phase I metabolism. The principal metabolic transformation involves UDP‑glucuronosyltransferase (UGT) mediated glucuronidation, producing an inactive N‑glucuronide metabolite. The glucuronide conjugates are water‑soluble and are eliminated unchanged via the kidneys. The renal clearance of cetirizine can be expressed as:

Cl_renal = (Urine rate × Plasma concentration) ÷ Dose

Given the high proportion of renal clearance, impaired renal function results in a proportional decrease in drug elimination. Adjusted dosing intervals (e.g., 48 h instead of 24 h) are recommended for patients with creatinine clearance < 30 mL/min.

Pharmacodynamic Mechanisms

Cetirizine’s antagonism of H1 receptors attenuates several histamine‑mediated responses:

• Vascular Effects: Inhibition of vasodilation and increased capillary permeability reduces edema.
• Neurological Effects: Blocking sensory nerve activation mitigates pruritus and nasal congestion.
• Immune Modulation: Reduced histamine release dampens mast cell degranulation, thereby decreasing the severity of allergic reactions.

The selectivity of cetirizine for peripheral H1 receptors is illustrated by its minimal affinity for muscarinic, adrenergic, and dopamine receptors, which contributes to its favorable safety profile.

Mathematical Relationships and Models

The time‑concentration profile of cetirizine can be approximated by a first‑order elimination model:

C(t) = C₀ × e^−k_el t

where C₀ is the initial concentration, k_el is the elimination rate constant, and t is time. The area under the concentration‑time curve (AUC) is calculated as:

AUC = Dose ÷ Clearance

Because clearance is largely renal, the AUC increases proportionally with the decline in renal function. For patients with a 50 % reduction in clearance, the AUC will approximately double, potentially elevating plasma concentrations beyond the therapeutic range.

Factors Influencing Pharmacokinetics and Dynamics

• Age: Elderly patients often exhibit reduced renal clearance, necessitating dose adjustment.
• Genetic Polymorphisms: Variations in UGT1A9 can alter glucuronidation rates, though clinical significance remains modest.
• Drug Interactions: Concomitant use of strong inhibitors of P-glycoprotein may increase central nervous system exposure, although such interactions are rare.
• Renal Impairment: As noted, diminished kidney function prolongs t_1/2 and increases AUC.

Clinical Significance

Therapeutic Applications

Cetirizine is indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and atopic dermatitis. Its rapid onset of action (within 1 h) and sustained effect over 24 h make it suitable for once‑daily dosing regimens. The drug’s minimal sedation facilitates use in populations where psychomotor performance is essential, such as occupational settings or during driving.

Safety Profile and Contraindications

Adverse effects reported in clinical trials are generally mild and transient, including headache, dry mouth, and fatigue. Serious allergic reactions are rare. Contraindications include hypersensitivity to cetirizine or any component of the formulation. Caution is advised in patients with hepatic impairment, though data are limited. In patients with severe renal impairment, dose adjustments are necessary to prevent accumulation.

Drug–Drug Interactions

Cetirizine is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes; therefore, interaction potential through the CYP system is negligible. However, co‑administration with medications that are strong P-glycoprotein inhibitors (e.g., ketoconazole) may modestly increase central nervous system exposure, potentially increasing the risk of sedation or dizziness. When combined with antihypertensive agents, cetirizine’s vasodilatory effects may potentiate hypotension, especially in volume‑depleted patients.

Pharmacogenomics Considerations

Although most studies focus on first‑generation antihistamines, emerging data suggest that polymorphisms in UGT1A9 may influence cetirizine clearance. Genotyping could be considered in patients with atypical responses or unexplained side effects, though routine testing is not currently recommended.

Clinical Applications/Examples

Case Scenario 1: Seasonal Allergic Rhinitis in a Working Professional

A 35‑year‑old male office worker presents with sneezing, nasal congestion, and itchy eyes during late spring. He reports that his current antihistamine causes drowsiness, impairing his job performance. Cetirizine at 10 mg once daily is initiated. Within 2 h, nasal symptoms improve without sedation. After 7 days, the patient reports no residual side effects and resumes normal activity. This case illustrates cetirizine’s suitability for individuals requiring alertness.

Case Scenario 2: Chronic Idiopathic Urticaria in an Elderly Patient

A 68‑year‑old woman experiences daily wheals and itching. She has stage I chronic kidney disease with a creatinine clearance of 35 mL/min. Cetirizine is prescribed at 10 mg once daily. After 4 weeks, urticaria frequency decreases, and the patient tolerates the medication well. Due to her renal impairment, dose adjustments are unnecessary for a 10‑mg once‑daily regimen, but a 48‑h dosing interval is considered if breakthrough symptoms occur.

Case Scenario 3: Drug Interaction with P‑Glycoprotein Inhibitor

A 45‑year‑old man with fungal infection is prescribed ketoconazole 200 mg twice daily. He also takes cetirizine 10 mg once daily for seasonal allergies. During the first week, he reports mild drowsiness and impaired concentration. The healthcare provider reduces the ketoconazole dose and monitors the patient. Symptoms resolve after 3 days, indicating a likely interaction mediated by increased central exposure to cetirizine.

Problem‑Solving Approach to Dose Adjustment

1. Assess renal function via estimated glomerular filtration rate (eGFR).
2. Determine appropriate dosing interval: for eGFR ≥ 60 mL/min, 10 mg q24h; for eGFR 30–59 mL/min, 10 mg q48h; for eGFR < 30 mL/min, consider 5 mg q48h.
3. Monitor for therapeutic response and adverse events.
4. Adjust dose or interval based on clinical feedback and renal function trends.

Summary / Key Points

• Cetirizine is a second‑generation antihistamine with high peripheral selectivity and low sedation risk.
• Its pharmacokinetic profile is characterized by oral bioavailability of ~80 %, moderate distribution, minimal hepatic metabolism, and predominant renal excretion.
• The drug’s elimination half‑life is 8–12 h in healthy adults, extending to 12–24 h in renal impairment.
• Pharmacodynamic action involves competitive antagonism of peripheral H1 receptors, reducing histamine‑mediated vascular and sensory responses.
• Contraindications include hypersensitivity to the drug; caution is advised in severe renal dysfunction.
• Drug interactions are minimal but may occur with potent P‑glycoprotein inhibitors, potentially increasing central nervous system exposure.
• Clinical scenarios demonstrate cetirizine’s effectiveness in allergic rhinitis, urticaria, and atopic dermatitis, with dose adjustments guided by renal function.
• Future research may elucidate the role of UGT polymorphisms in cetirizine pharmacokinetics, potentially informing personalized therapy.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.